Xellia Pharmaceuticals and Alpharma v Commission: ECFI 8 Sep 2016

ECJ (Judgment) Competition – Agreements, decisions and concerted practices – Market for antidepressant medicinal products containing the active pharmaceutical ingredient citalopram – Concept of restriction of competition ‘by object’ – Potential competition – Generic medicinal products – Barriers to market entry resulting from the existence of patents – Agreement concluded between a patent holder and a generic undertaking – Duration of the Commission’s investigation – Rights of the defence – Fines – Legal certainty – Principle that penalties must have a proper legal basis)

ECLI:EU:T:2016:460, [2016] EUECJ T-471/13

European, Commercial

Updated: 23 January 2022; Ref: scu.569390